De Rucci Healthy Sleep Co., Ltd.
SZSE:001323.SZ
34.38 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,235.819 | 1,413.935 | 1,201.254 | 1,773.066 | 1,406.094 | 1,442.194 | 957.197 | 1,659.21 | 1,401.427 | 1,507.265 | 1,244.773 | 2,209.313 | 1,462.797 | 1,566.607 | 1,242.325 |
| Cost of Revenue
| 626.178 | 721.23 | 598.821 | 900.313 | 689.213 | 689.381 | 494.048 | 887.796 | 738.826 | 800.157 | 684.501 | 1,207.706 | 830.537 | 844.314 | 683.562 |
| Gross Profit
| 609.642 | 692.705 | 602.434 | 872.753 | 716.881 | 752.813 | 463.149 | 771.415 | 662.601 | 707.108 | 560.272 | 1,001.607 | 632.259 | 722.292 | 558.762 |
| Gross Profit Ratio
| 0.493 | 0.49 | 0.502 | 0.492 | 0.51 | 0.522 | 0.484 | 0.465 | 0.473 | 0.469 | 0.45 | 0.453 | 0.432 | 0.461 | 0.45 |
| Reseach & Development Expenses
| 53.677 | 48.691 | 45.869 | 51.043 | 60.66 | 39.966 | 34.088 | 50.666 | 36.77 | 38.301 | 32.552 | 43.85 | 49.168 | 29.295 | 32.767 |
| General & Administrative Expenses
| 219.646 | -45.044 | 81.132 | -154.063 | 201.994 | -44.308 | 64.565 | -164.856 | 204.208 | 15.786 | 17.533 | -139.283 | 81.643 | 61.18 | 66.046 |
| Selling & Marketing Expenses
| 503.017 | 343.442 | 318.898 | 407.089 | 414.326 | 335.27 | 249.186 | 405.911 | 409.316 | 351.924 | 289.37 | 509.993 | 405.853 | 405.298 | 274.935 |
| SG&A
| 409.147 | 388.664 | 400.03 | 253.027 | 616.32 | 290.962 | 313.751 | 241.056 | 613.524 | 367.709 | 306.903 | 370.71 | 487.496 | 466.478 | 340.981 |
| Other Expenses
| -326.763 | -1.172 | -0.037 | -10.295 | 2.312 | 2.304 | -0.244 | 4.481 | -1.104 | -2.534 | -0.365 | -0.056 | -1.795 | 3.071 | -1.067 |
| Operating Expenses
| 449.577 | 438.526 | 449.547 | 536.666 | 565.133 | 458.091 | 352.684 | 534.149 | 524.115 | 475.981 | 405.342 | 670.171 | 543.775 | 506.458 | 380.552 |
| Operating Income
| 145.8 | 254.179 | 169.448 | 355.667 | 173.225 | 311.085 | 125.254 | 296.347 | 145.563 | 227.212 | 149.803 | 333.591 | 97.078 | 215.286 | 171.71 |
| Operating Income Ratio
| 0.118 | 0.18 | 0.141 | 0.201 | 0.123 | 0.216 | 0.131 | 0.179 | 0.104 | 0.151 | 0.12 | 0.151 | 0.066 | 0.137 | 0.138 |
| Total Other Income Expenses Net
| 28.121 | 21.252 | 16.525 | 12.714 | 2.312 | 2.304 | 11.854 | 79.267 | -1.104 | -3.546 | -0.365 | -0.056 | -1.795 | 3.071 | -1.067 |
| Income Before Tax
| 173.922 | 275.557 | 169.411 | 345.372 | 175.537 | 313.39 | 125.01 | 300.828 | 144.459 | 224.679 | 149.438 | 333.535 | 95.283 | 218.357 | 170.643 |
| Income Before Tax Ratio
| 0.141 | 0.195 | 0.141 | 0.195 | 0.125 | 0.217 | 0.131 | 0.181 | 0.103 | 0.149 | 0.12 | 0.151 | 0.065 | 0.139 | 0.137 |
| Income Tax Expense
| 24.78 | 43.503 | 28.162 | 61.459 | 12.919 | 58.92 | 23.743 | 17.171 | 26.167 | 41.803 | 25.338 | 60.097 | 8.68 | 28.436 | 34.161 |
| Net Income
| 149.142 | 231.928 | 141.249 | 283.913 | 162.617 | 254.47 | 101.267 | 283.657 | 118.292 | 182.875 | 124.1 | 273.437 | 86.603 | 189.921 | 136.482 |
| Net Income Ratio
| 0.121 | 0.164 | 0.118 | 0.16 | 0.116 | 0.176 | 0.106 | 0.171 | 0.084 | 0.121 | 0.1 | 0.124 | 0.059 | 0.121 | 0.11 |
| EPS
| 0.38 | 0.59 | 0.36 | 0.71 | 0.41 | 0.64 | 0.25 | 0.71 | 0.3 | 0.46 | 0.34 | 0.68 | 0.22 | 0.47 | 0.38 |
| EPS Diluted
| 0.38 | 0.59 | 0.36 | 0.71 | 0.41 | 0.64 | 0.25 | 0.71 | 0.3 | 0.46 | 0.34 | 0.68 | 0.22 | 0.47 | 0.38 |
| EBITDA
| 177.079 | 351.741 | 244.154 | 410.772 | 242.532 | 378.501 | 190.029 | 381.772 | 225.403 | 304.838 | 170.246 | 398.215 | 159.964 | 283.783 | 207.682 |
| EBITDA Ratio
| 0.143 | 0.229 | 0.142 | 0.195 | 0.126 | 0.217 | 0.128 | 0.166 | 0.105 | 0.198 | 0.176 | 0.16 | 0.056 | 0.18 | 0.171 |